Clinical Practice Guidelines for Management of Bipolar Disorder

Shah, Nilesh; Grover, Sandeep; Rao, Gopal

doi:10.4103/0019-5545.196974

Cited by 84 publications

(94 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the first-line treatment for chronic patients with BD is the use of mood stabilizers (e.g. lithium, valproate) [43], but second generation antipsychotic medications have also been found effective for managing acute symptoms of mania [44]. …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis and Mood Disorders

et al. 2018

View full text Add to dashboard Cite

Purpose of review The present review will provide an overview of the neurobiology, epidemiology, clinical impact, and treatment of cannabis use disorder (CUD) in mood disorders. Recent findings Patients with mood disorders including major depressive disorder (MDD) and bipolar disorder (BD) have higher rates of cannabis use, and CUD compared to the general population. Reasons for this association are not clear, nor are the putative therapeutic effects of cannabis use, or its components delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in these illnesses. The evidence surrounding treatments for patients with this comorbidity is lacking, with more support for psychotherapeutic treatments compared with pharmacological treatments. Summary Cannabis use may be associated mood disorders, but more research is needed to increase our understanding of the mechanisms for this association, and to develop more effective treatments for this comorbidity.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Cognitive Behavioral Therapy (CBT) is the first-line evidence-based psychotherapeutic treatment for all mood disorders [42, 44]. This psychotherapy is tailored to the individual diagnosis and also has demonstrated some efficacy in the treatment of CUD [61–63].…”

Section: Methodsmentioning

confidence: 99%

Cannabis and Mood Disorders

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Use of various treatment options is guided by the phase of illness including mania, hypomania, depression or mixed, in which patient presents to the clinician (Avasthi et al, 2004; Shah et al, 2017). Clinical pharmacy related services including patient education results in better outcomes from the therapy including improvement of medication adherence and QOL of patients (Parthasarathi et al, 2004).…”

Section: Methodsmentioning

confidence: 99%

Impact of Pharmacist–Psychiatrist Collaborative Patient Education on Medication Adherence and Quality of Life (QOL) of Bipolar Affective Disorder (BPAD) Patients

et al. 2017

View full text Add to dashboard Cite

Background: Bipolar Affective Disorder (BPAD) is one of the leading causes of disability globally. Medication non-adherence and low quality of life (QOL) are the major challenges associated with the treatment of BPAD patients.Objective: Aim of this study was to assess the impact of pharmacist–psychiatrist collaborative patient education on medication adherence and QOL of BPAD patients.Methodology: A prospective randomized control study was conducted in the psychiatry outpatient department in a tertiary care setting. The eligible patients were enrolled and randomized into test (collaborative care) and control (usual care) groups. Patient education was provided by pharmacists to the test group patients, along with the usual care provided to all the patients. Patients were followed for three follow-ups of nearly 1 month intervals. Medication adherence and QOL were assessed by Medication Adherence Rating Scale and WHOQOL-BREF questionnaire, respectively. T-test was used and P-values < 0.05 were considered statistically significant.Results: Out of 75 patients enrolled, 73 patients were followed for all the three follow-ups and completed the study. Thirty-eight patients belonged to test and 35 were in control group. The mean age of patients was 34.21 ± 10.91 years. Forty-eight (65.75%) patients belonged to age group of 18–39 years. There were 41 males (56.16%) and 32 female patients (43.83%) in the study. Mean improvement in medication adherence and QOL of the test and control groups were found to be 2.06 ± 0.15 (<0.001) and 13.8 ± 10.5 (<0.05), respectively.Conclusion: This study concluded that pharmacist–psychiatrist collaborative patient education can significantly improve the medication adherence and QOL of the BPAD patients. Statistically significant results indicating improved patient care and outcomes were possible when pharmacists worked as a team with psychiatrists.

show abstract

“…Many patients with bipolar disorder fail to respond acutely to adequate pharmacotherapy (Geddes & Miklowitz, 2013). For those patients who do experience symptomatic improvements following pharmacological treatment, many experience frequent and intolerable side effects that lead to medication nonadherence and/or discontinuation (Matson et al, 2006;Shah, Grover, & Rao, 2017). In addition, several patients with BD suffer from an increased medical burden and clinicians must thus be mindful of interactions among the medications that patients could be taking to manage multiple medical concerns (Kemp et al, 2014;Martin, Williams, Haskard, & Dimatteo, 2005).…”

Section: Introductionmentioning

confidence: 99%

Clinical applications of transcranial magnetic stimulation in bipolar disorder

Gold

Ornelas²,

Cirillo³

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

Background Many patients with bipolar disorder (BD) fail to experience benefit following traditional pharmacotherapy, necessitating alternative treatment options that will enable such patients to achieve remission. Transcranial magnetic stimulation (TMS) is a relatively new, noninvasive neuromodulation technique that involves the application of magnetic pulses on hyperactive or hypoactive cortical brain areas. We evaluated the existing literature on TMS as a treatment for BD across varied mood states. Methods We searched PubMed up to October 2018 for original data articles published in English that evaluated outcomes in a bipolar sample across depressive, manic, mixed, and maintenance phases of BD. Results Clinical trials of TMS for BD particularly suggest the potential of repetitive TMS for reducing depressive symptoms. Studies of TMS for mania have yielded more mixed findings. Few studies have evaluated TMS in other phases of the bipolar illness. TMS is generally associated with mild side effects though, in a few studies, it has been shown to contribute to a manic switch in previously depressed bipolar patients. Conclusions Transcranial magnetic stimulation is a promising approach for treating patients with BD who have failed to respond to pharmacological or psychosocial treatment. Future research should more clearly elucidate which TMS protocols may be most effective for a given bipolar patient.

show abstract

Clinical Practice Guidelines for Management of Bipolar Disorder

Cited by 84 publications

References 39 publications

Cannabis and Mood Disorders

Cannabis and Mood Disorders

Impact of Pharmacist–Psychiatrist Collaborative Patient Education on Medication Adherence and Quality of Life (QOL) of Bipolar Affective Disorder (BPAD) Patients

Clinical applications of transcranial magnetic stimulation in bipolar disorder

Contact Info

Product

Resources

About